ClinicalTrials.gg
CompletedNCT07949214Updated Nov 19, 2026

Comparative Study Between Autologous Platelet Rich Plasma (A-PRP) Versus Trans Obturator Tape (TOT) for Treatment of Female Genuine Stress Urinary Incontinence (SUI)

An interventional study of Autologous Platelet-Rich Plasma (A-PRP) Injection and Transobturator Tape (TOT) Procedure in Urinary Incontinence, Stress, sponsored by Benha University. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Benha University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jun 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Urinary Incontinence, Stress with a site in Egypt — 15 open to participants now, 19 under way, none of them phase 3. Urinary Incontinence, Stress · Egypt.

Enrollment
10th of 32
80 · median 60
Started
2025
with 5 others
No phase
24 of 40
11 open now
Registered
40th of 40
by date
Lead sponsor
4 of 40
Benha University

Among the 40 studies in Urinary Incontinence, Stress with a site in Egypt, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, and was the 40th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

15 of the 40 studies in Urinary Incontinence, Stress with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Urinary Incontinence, Stress with a site in Egypt, or all of them as a file.
02

Study summary

This study aimed to compare the effectiveness and safety of autologous platelet-rich plasma (A-PRP) injections and transobturator tape (TOT) surgery for treating stress urinary incontinence in women.

This prospective, randomized, parallel-group clinical trial included 80 women aged 18-65 years with confirmed stress urinary incontinence. Participants were randomly assigned to receive either A-PRP injections or TOT surgery, with 40 women in each group.

Participants were assessed before treatment and at 3 and 6 months after treatment. The primary outcome was the objective cure rate at 6 months, assessed using a standardized stress test. Secondary outcomes included urinary symptoms, quality of life, urine leakage, urodynamic measurements, adverse events, and the need for additional treatment.

The study was conducted at a tertiary-care academic institution in Egypt between June 2025 and June 2026.

Read the detailed description

Stress urinary incontinence (SUI) is a common condition in women, characterized by involuntary urine leakage during activities that increase intra-abdominal pressure, such as coughing, sneezing, or physical exertion. It can significantly affect quality of life and daily activities.

Transobturator tape (TOT) is an established surgical treatment for SUI that provides support to the mid-urethra. However, surgical treatment may be associated with complications, including mesh-related adverse events.

Autologous platelet-rich plasma (A-PRP) is a minimally invasive regenerative treatment obtained from the patient's own blood. It contains concentrated platelets and growth factors that may promote tissue repair and improve urethral support.

This prospective, randomized, parallel-group comparative trial evaluated the efficacy and safety of A-PRP injections versus TOT surgery in 80 women aged 18-65 years with urodynamically confirmed SUI.

Eligible participants were randomly allocated in a 1:1 ratio to two treatment groups. The A-PRP group received a transvaginal injection of approximately 5 mL of autologous platelet-rich plasma into the anterior vaginal wall at three periurethral sites. The TOT group underwent an outside-in transobturator mid-urethral sling procedure using polypropylene mesh tape.

Clinical outcomes were assessed at baseline and at 3 and 6 months after treatment. The primary outcome was objective cure at 6 months, defined by a negative standardized stress test in the absence of symptomatic SUI.

Secondary outcomes included changes in International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), Urogenital Distress Inventory-6 (UDI-6), and Incontinence Quality of Life (I-QOL) scores, 24-hour pad test results, urodynamic parameters, adverse events, and the need for additional treatment.

03

Conditions studied

  • Urinary Incontinence, Stress

Keywords

  • stress urinary incontinence
  • autologous platelet-rich plasma
  • transobturator tape
  • mid-urethral sling
  • randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-65 years.

Symptomatic stress urinary incontinence for at least 6 months.

Positive stress test.

Urodynamically confirmed stress urinary incontinence without evidence of detrusor overactivity.

Willingness and ability to comply with the study protocol and follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  • Mixed urinary incontinence with a predominant urge component.

Recurrent stress urinary incontinence following previous anti-incontinence surgery.

Active urinary tract infection.

Moderate to severe pelvic organ prolapse (POP-Q stage II or higher).

Significant cardiac or pulmonary comorbidity rendering the patient unfit for general or regional anesthesia.

Known coagulopathy or bleeding diathesis.

Uncontrolled diabetes mellitus ( > 8.5%).

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    A-PRP Group

    Participants in this group received a transvaginal injection of approximately 5 mL of autologous platelet-rich plasma (A-PRP) into the anterior vaginal wall at three periurethral sites, approximately 1 cm proximal to the urethral meatus. The procedure was performed under local anesthesia using 2% lidocaine gel.

    Procedure: Autologous Platelet-Rich Plasma (A-PRP) Injection

  • Active comparator
    TOT Group

    Participants in this group underwent a transobturator tape (TOT) procedure using a polypropylene monofilament mid-urethral sling inserted through an outside-in transobturator approach under spinal or general anesthesia. The tape was positioned tension-free beneath the mid-urethra.

    Procedure: Transobturator Tape (TOT) Procedure

Interventions

  • ProcedureAutologous Platelet-Rich Plasma (A-PRP) Injection

    Approximately 15 mL of autologous venous blood was collected and centrifuged at 1,500 rpm for five minutes to obtain approximately 5 mL of platelet-rich plasma. The A-PRP was injected transvaginally into the anterior vaginal wall at three periurethral sites, approximately 1 cm proximal to the urethral meatus, using a 27-gauge needle under local anesthesia with 2% lidocaine gel.

  • ProcedureTransobturator Tape (TOT) Procedure

    Participants underwent an outside-in transobturator mid-urethral sling procedure using polypropylene monofilament mesh tape under spinal or general anesthesia. The tape was positioned tension-free beneath the mid-urethra, and intraoperative cystoscopy was performed to exclude bladder or urethral perforation.

06

What researchers measure

Primary outcomes

  1. Objective Cure Rate at 6 Months

    The proportion of participants achieving objective cure, defined as a negative standardized cough stress test in the absence of symptomatic stress urinary incontinence. The test was performed with a comfortably full bladder (at least 200 mL) in the lithotomy position. Urine leakage observed during coughing was considered a positive test.

    Time frame: 6 months after intervention

Secondary outcomes

  1. Change in ICIQ-UI SF Score

    Change from baseline in the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) total score. Scores range from 0 to 21, with higher scores indicating more severe urinary incontinence symptoms.

    Time frame: Baseline, 3 months, and 6 months after intervention

  2. Change in 24-Hour Pad Test Weight

    Change from baseline in urine leakage measured using a 24-hour pad test. Participants wore pre-weighed continence pads for 24 hours, and urine loss was determined from the change in pad weight in grams, corrected for evaporation.

    Time frame: Baseline, 3 months, and 6 months after intervention

  3. Change in Maximum Urethral Closure Pressure

    Change from baseline in maximum urethral closure pressure (MUCP), measured in cmH2O using multichannel urodynamic testing.

    Time frame: Baseline and 6 months after intervention

07

Study locations

1 site
  • Benha University Hospitals
    Banhā, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jun 2026, 12 months.

Of 227 non-industry interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 12 months is below that.

Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartActual
Jun 10, 2025
Primary completionActual
Jun 12, 2026
CompletionActual
Jun 12, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949214
Lead sponsor
Benha University
Responsible party
Ahmed Hashem Mohammed (Principal Investigator, Benha University) — Principal investigator
First posted
Nov 19, 2026
Start date
Jun 10, 2025
Primary completion
Jun 12, 2026
Completion
Jun 12, 2026
Last update
Nov 19, 2026

Study contacts

Ahmed H Mohamed, MD
principal investigator · Benha University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion